Call us today for a free and confidential consultation with a Paul & Hanley LLP attorney.  We are one of the nation's leading toxic tort litigation firms  We'll discuss your specific case and give you honest answers to your questions.

Our toll-free number is (800) 933-2244.  The mesothelioma lawyers of Paul & Hanley look forward to helping you.

Northern California
1608 Fourth Street,
Suite 300
Berkeley, CA 94710
Phone: 510-559-9980
Fax: 510-559-9970
Map

Southern California
5716 Corsa Ave,
Suite 203
Westlake Village, CA 91362
Phone: 818-865-2807
Fax: 818-865-0805
Map

811 W. Seventh St.
Suite 206
Los Angeles, CA 90017
Phone: 213-689-3278
Fax: 213-689-4309
Map

Wisconsin
250 East Wisconsin Ave. 
Suite 1800
Milwaukee, WI 53202
Phone: 414-289-3135
Toll Free: 800-933-2244
 

 


AZD2171 (cediranib, Recentin)

Cediranib (tentative trade name Recentin), also known as AZD2171, is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases.[1][2][3]

It is being developed by AstraZeneca as a possible anti-cancer chemotherapeutic agent for oral administration.

Beginning in 2007, it is undergoing Phase I clinical trials for the treatment of non-small cell lung cancer, kidney cancer, and colorectal cancer in adults, as well as tumors of the central nervous system in children.  Phase I trials of interactions with other drugs used in cancer treatment are also underway.  As of September 2009 there is only one mesothelioma treatment trial using this drug.

On February 27, 2008, AstraZeneca announced that the use of Recentin in non-small cell lung cancer will not progress into phase III after failing to meet its main goal.

References

  1. ^ Wedge SR, Kendrew J, Hennequin LF, et al. (May 2005). "AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer". Cancer Res. 65 (10): 4389–400. doi:10.1158/0008-5472.CAN-04-4409. PMID 15899831. http://cancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=15899831. 
  2. ^ Goss G, Shepherd FA, Laurie S, et al. (December 2008). "A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group". Eur. J. Cancer 45: 782. doi:10.1016/j.ejca.2008.10.022. PMID 19091548. http://linkinghub.elsevier.com/retrieve/pii/S0959-8049(08)00868-X. 
  3. ^ Nikolinakos P, Heymach JV (June 2008). "The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies". J Thorac Oncol 3 (6 Suppl 2): S131–4. doi:10.1097/JTO.0b013e318174e910. PMID 18520296. http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?doi=10.1097/JTO.0b013e318174e910. 

External links